anti-FLT3 CAR-T
2021136
Phase 2 mab active
Quick answer
anti-FLT3 CAR-T for Acute Myeloid Leukemia is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Acute Myeloid Leukemia
- Phase
- Phase 2
- Modality
- mab
- Status
- active